HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

J Michael Conlon Selected Research

Infections

10/2020Selection of antimicrobial frog peptides and temporin-1DRa analogues for treatment of bacterial infections based on their cytotoxicity and differential activity against pathogens.
11/2019Peptidomic analysis in the discovery of therapeutically valuable peptides in amphibian skin secretions.
11/2014Anti-cancer, immunoregulatory, and antimicrobial activities of the frog skin host-defense peptides pseudhymenochirin-1Pb and pseudhymenochirin-2Pa.
6/2013Evaluation of the skin peptide defenses of the Oregon spotted frog Rana pretiosa against infection by the chytrid fungus Batrachochytrium dendrobatidis.
9/2012Host-defense peptides in skin secretions of the tetraploid frog Silurana epitropicalis with potent activity against methicillin-resistant Staphylococcus aureus (MRSA).
4/2012Efficacy of six frog skin-derived antimicrobial peptides against colistin-resistant strains of the Acinetobacter baumannii group.
4/2012Analogues of the frog skin peptide alyteserin-2a with enhanced antimicrobial activities against Gram-negative bacteria.
4/2012Peptides with antimicrobial and anti-inflammatory activities that have therapeutic potential for treatment of acne vulgaris.
9/2005Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.
6/2002Activity of antimicrobial skin peptides from ranid frogs against Batrachochytrium dendrobatidis, the chytrid fungus associated with global amphibian declines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


J Michael Conlon Research Topics

Disease

30Type 2 Diabetes Mellitus (MODY)
02/2024 - 02/2008
21Body Weight (Weight, Body)
01/2024 - 11/2008
18Insulin Resistance
02/2024 - 08/2013
16Obesity
01/2024 - 08/2013
14Neoplasms (Cancer)
03/2024 - 11/2010
10Infections
10/2020 - 06/2002
10Tetraploidy
01/2016 - 06/2010
7Adenocarcinoma of Lung
10/2017 - 01/2013
5Glucose Intolerance
01/2024 - 10/2017
4Adenocarcinoma
10/2017 - 11/2013
2Carcinoma (Carcinomatosis)
07/2017 - 11/2010
2Hypertension (High Blood Pressure)
07/2012 - 03/2006
2Hepatocellular Carcinoma (Hepatoma)
06/2009 - 07/2008
2Bradycardia
09/2007 - 08/2003
1Decompression Sickness (Bends)
02/2021
1Bacterial Infections (Bacterial Infection)
10/2020
1Skin Diseases (Skin Disease)
11/2019
1Sepsis (Septicemia)
11/2019
1Weight Loss (Weight Reduction)
10/2017
1Metabolic Syndrome (Dysmetabolic Syndrome X)
10/2015
1Complementation Group D Xeroderma Pigmentosum
10/2015
1Necrosis
09/2013
1Hemorrhage
09/2013
1Dehydration (Water Stress)
07/2012
1Acne Vulgaris
04/2012
1Pheochromocytoma
11/2010
1Carcinoid Tumor (Carcinoid)
11/2010
1Hyperemia
09/2007
1Hemolysis
09/2006
1HIV Infections (HIV Infection)
09/2005

Drug/Important Bio-Agent (IBA)

57Peptides (Polypeptides)IBA
03/2024 - 06/2002
23Glucose (Dextrose)FDA LinkGeneric
02/2024 - 11/2008
18Insulin (Novolin)FDA Link
08/2021 - 03/2002
14Antimicrobial Cationic PeptidesIBA
02/2024 - 01/2012
7Glucagon (Glukagon)FDA Link
11/2022 - 01/2016
7Norepinephrine (Noradrenaline)FDA LinkGeneric
12/2014 - 06/2010
6Blood Glucose (Blood Sugar)IBA
01/2024 - 10/2017
5IncretinsIBA
01/2024 - 07/2014
4LipidsIBA
02/2024 - 10/2015
4Glucagon-Like Peptide 1 (GLP 1)IBA
01/2022 - 10/2017
4CeruletideIBA
01/2021 - 06/2011
3peptide-Gly-Leu-amideIBA
02/2024 - 01/2012
3esculentin steroidIBA
10/2017 - 01/2013
3Antimicrobial PeptidesIBA
09/2005 - 06/2002
2Exenatide (Byetta)FDA Link
12/2018 - 10/2017
2Triglycerides (Triacylglycerol)IBA
04/2016 - 10/2015
2CytokinesIBA
11/2014 - 04/2012
2VenomsIBA
01/2014 - 09/2013
2Proteins (Proteins, Gene)FDA Link
09/2013 - 07/2012
1Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)IBA
01/2023
1Activins (Activin)IBA
01/2023
1Monoclonal AntibodiesIBA
01/2023
1setmelanotideIBA
01/2023
1bimagrumabIBA
01/2023
1gastric inhibitory polypeptide receptorIBA
01/2022
1Glucagon-Like Peptide-1 ReceptorIBA
01/2022
1semaglutideIBA
01/2022
1tirzepatideIBA
01/2022
1Streptozocin (Streptozotocin)FDA Link
08/2021
1Hypoglycemic Agents (Hypoglycemics)IBA
01/2021
1plasticinIBA
04/2019
1temporinIBA
01/2018
1octanoic acid (caprylic acid)IBA
10/2017
1EnzymesIBA
07/2016
1AmylasesFDA Link
07/2016
1Insulin SecretagoguesIBA
04/2016
1CholesterolIBA
04/2016
1Lysine (L-Lysine)FDA Link
02/2016
1SecretagoguesIBA
10/2015
1Trefoil FactorsIBA
10/2015
1Immunomodulating AgentsIBA
01/2014
1Anti-Infective Agents (Microbicides)IBA
01/2014
1snake venom neurotoxin FIBA
01/2014
1Hymenochirus boettgeri hymenochirin-1BIBA
11/2013
1Lithobates chiricahuensis esculentin-2CHaIBA
01/2013
1Angiotensin IIIBA
07/2012
1Anti-Bacterial Agents (Antibiotics)IBA
04/2012
1Glycine (Aminoacetic Acid)FDA LinkGeneric
01/2012
1AmidesIBA
01/2012
1Leucine (L-Leucine)FDA Link
01/2012
1MagaininsIBA
01/2012
1Complement System Proteins (Complement)IBA
11/2010
1Immune Sera (Antisera)IBA
11/2010
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
11/2010
1ChromograninsIBA
11/2010
1Biomarkers (Surrogate Marker)IBA
11/2010
1secretoneurinIBA
11/2010
1Chromogranin BIBA
11/2010
1Chromogranin AIBA
11/2010
1Secretogranin IIIBA
11/2010
1pancreastatinIBA
11/2010
1TachykininsIBA
09/2007
1NeurotensinIBA
09/2007
1CatecholaminesIBA
03/2006

Therapy/Procedure

15Therapeutics
02/2024 - 11/2010
5Intraperitoneal Injections
08/2021 - 11/2008
2Injections
07/2012 - 03/2006
1Drug Therapy (Chemotherapy)
11/2020
1Glycemic Control
10/2017
1Intra-Arterial Injections
09/2007